Scientific Publications
CYB003
American College of Neuropsychopharmacology Annual Meeting – December 8-11, 2024
Poster #M77: CYB003 produces robust and enduring antidepressant effects in patients with Major Depressive Disorder (MDD)
Read the Abstract
View the Poster
American College of Neuropsychopharmacology Annual Meeting – December 3-6, 2023
Poster #M83: Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CYB003, a Deuterated Psilocybin Analog in Patients with Major Depressive Disorder
ACNP 62nd Annual Meeting: Poster Abstracts P1 – P250. Neuropsychopharmacol. 48 (Suppl 1), 63–210 (2023).
Read the Abstract
View the Poster
American College of Neuropsychopharmacology Annual Meeting – December 4-7, 2022
Poster #P361: In Vitro and in Vivo Profile of CYB003: A Novel, Deuterated Psilocybin Analog for the Potential Treatment of Major Depressive Disorder
ACNP 61st Annual Meeting: Poster Abstracts P271-P540. Neuropsychopharmacol. 47 (Suppl 1), 220–370 (2022).
Read the Abstract
View the Poster
Poster #P362: Pharmacokinetic Profile of CYB003: A Novel, Deuterated Psilocybin Analog for the Potential Treatment of Major Depressive Disorder
ACNP 61st Annual Meeting: Poster Abstracts P271-P540. Neuropsychopharmacol. 47 (Suppl 1), 220–370 (2022).
Read the Abstract
View the Poster
Society for Neuroscience – November 12-16, 2022
Pharmacological and Pharmacokinetic Profile of CYB003, A Novel, Orally Active Analog of Psilocybin for the Potential Treatment of Major Depressive Disorder
View the Poster
From Research to Reality:
Global Summit on Psychedelic-Assisted Therapies and Medicine – May 27-29, 2022
Pharmacological and Pharmacokinetic Profile of CYB003, A Novel, Orally Active Analog of Psilocybin
View the Poster
DMT/Deuterated DMT
Publications
Good et al. (2023). Pharmacokinetics of N,N-dimethyltryptamine in Humans. European journal of drug metabolism and pharmacokinetics, 48(3), 311–327.
Read More
Layzell et al. (2023). Discovery and In Vitro Characterization of SPL028: Deuterated N,N-Dimethyltryptamine. ACS medicinal chemistry letters, 14(9), 1216–1223.
Read More
For access, please email irteam@cybin.com
James et al. (2024). Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial. Frontiers in psychiatry, 14, 1305796.
Posters
American College of Neuropsychopharmacology Annual Meeting – December 8-11, 2024
Poster #M59: SPL026 (DMT fumarate) in combination with Selective Serotonin Reuptake Inhibitors (SSRIs) for patients with Major Depressive Disorder (MDD)
Read the Abstract
View the Poster
American College of Neuropsychopharmacology Annual Meeting – December 3-6, 2023
Poster #M32: Preclinical Characterization of CYB004: A Novel, Deuterated N,N-dimethyltryptamine (DMT) Analog for the Potential Treatment of Generalized Anxiety Disorder (GAD)
ACNP 62nd Annual Meeting: Poster Abstracts P1 – P250. Neuropsychopharmacol. 48 (Suppl 1), 63–210 (2023).
Read the Abstract
View the Poster
Early Clinical Development of a Deuterated N,N-Dimethyltryptamine (DMT) Analog for the Treatment of Mental Health Conditions
Read the Abstract
View the Poster
British Association for Psychopharmacology (BAP) 2023 Summer Meeting – July 23-26, 2023
In vivo characterisation of SPL028: a deuterated derivative of N,N-dimethyltryptamine, developing a treatment for mental health disorders
Read the Abstract
View the Poster
Discovery and in vitro characterization of deuterated N,N-dimethyltryptamine for the treatment of mental health disorders
View the Poster
Results from the Phase 1 Small Pharma trial of SPL026 in psychedelic-naïve healthy volunteers
View the Poster
Read the BAP abstracts
British Neuroscience Association (BNA) International Festival of Neuroscience – April 23-26, 2023
• In vivo characterisation of SPL028: a deuterated derivative of N,N-dimethyltryptamine, developing a treatment for mental health disorders
Read the Abstract
View the Poster
CNS Summit 2022
Phase I Results from a Phase I/IIa clinical trial of SPL026-assisted psychedelic therapy
View the Poster
Phenethylamines
Publications
Varty et al. (2024). Synthesis and Structure-Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT2 Receptor Agonist. Journal of medicinal chemistry, 67(8), 6144–6188.
Read More
Posters
American College of Neuropsychopharmacology Annual Meeting – December 3-6, 2023
Poster #M147: Discovery And Preclinical Characterization of 2,5-dimethoxy-4-thiofluoroalkyl Phenethylamines as Potent and Long-acting Serotonin 5-HT2 Receptor Agonists
ACNP 62nd Annual Meeting: Poster Abstracts P1 – P250. Neuropsychopharmacol. 48 (Suppl 1), 63–210 (2023).
Read the Abstract
View the Poster
EMBARK
Brennan, W., Kelman, A. R., & Belser, A. B. (2023).
A systematic review of reporting practices in psychedelic clinical trials:
psychological support, therapy, and psychosocial interventions.
Psychedelic Medicine, 1(4), 218-229.
Read More
Brennan, W. and Belser, A.B. (2022). Models of Psychedelic-Assisted Psychotherapy:
A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model.
Frontiers in Psychology 13:866018.
Read More
